tirzepatide march 2025 https://investor.lilly.com/news-releases/news-release-details/zepbound- tirzepatide-most-prescribed-weight-management “Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound What are the changes to

CrossRef Longitudinal study of factors associated with the anti-cancer efficacy and liver function in HCC patients treated with TACE in combination with percutaneous ablation Huhu Ren, Jian Chen, Zhiqun Wu, Chen Li Frontiers in Oncology .2025;[Epub] CrossRef A Review of Risk Prediction Model for Hepatocellular Carcinoma in Chronic Hepatitis B Jiwon Yang, Mark D

Curexa received an FDA warning letter in 2023 for compounding violations, and AnazaoHealth has prior FDA enforcement actions in its history

There are no routine provider check-ins, no required follow-up visits, and no dose-adjustment cadence laid out for patients after approval

Banting lecture

The study examines the prevalence of false-positive findings and explores factors contributing to test interference, shedding light on the clinical implications of semaglutide use in drug testing scenarios